6-K
Immatics N.V. (IMTX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGNPRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
November 1, 2021
Commission File Number: 001-39363
IMMATICS N.V.
Paul-Ehrlich-Straße 15
72076 Tübingen, Federal Republic of Germany
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
| Form 20-F | ☒ | Form 40-F | ☐ |
|---|
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM6-K
On November 1, 2021, Immatics N.V. (the “Company”) issued a press release announcing its presentations at the Society for Immunotherapy of Cancer’s 36th Annual Meeting. A copy the press release is attached hereto as Exhibit 99.1.
EXHIBIT INDEX
| Exhibit No. | Description |
|---|---|
| 99.1 | Press release dated November 1, 2021 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| IMMATICS N.V. | ||
|---|---|---|
| Date: November 1, 2021 | ||
| By: | /s/ Harpreet Singh | |
| Name: | Harpreet Singh | |
| Title: | Chief Executive Officer |
Exhibit 99.1
PRESS RELEASE
Immatics****to Present Update on Lead ACTengine^®^ Program IMA203 Targeting PRAME at theSociety for Immunotherapy of Cancer’s 36th Annual Meeting
Houston,Texas and Tuebingen, Germany, November 1,2021 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its ACTengine^®^ IMA203 trial in a late-breaking oral presentation as well as an update on Immatics’ next-generation CD8ab TCR-T approach at the 36^th^Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC). The conference will take place, both in person and virtually, from November 10 - 14, 2021.
Today, SITC announced presentation titles and timings as follows:
IMA203 Phase1a Clinical Data Update:
PresentationTitle: Safety and anti-tumor activity of TCR-engineered autologous, PRAME-directed T cells across multiple advanced solid cancers at low doses – clinical update on the ACTengine^®^ IMA203 trial
Speaker: Martin Wermke, MD, Coordinating Investigator of Immatics ACTengine^®^ trials in Germany and Head of the Early Clinical Trial Unit of the National Center for Tumor Diseases Dresden (NCT/UCC) at the University Hospital Carl Gustav Carus in Dresden, Germany
**Abstract Number:**959
Category: Late-breaking oral abstract presentation
Date & Time: Saturday, November 13, 2021; 12:00 - 12:15 pm EDT
Next-generationCD8ab TCR-T approach - Preclinical Data Update:
Presentation Title: Improved anti-tumor activity of next-generation TCR-engineered T cells through CD8 co-expression
Speaker: Mamta Kalra, PhD, Director CMC (Process Development) at Immatics
Abstract Number: 163
Category: Poster abstract presentation
Date & Time: Friday, November 12, 2021; Poster Hall Hours: 7 am–8:30 pm EDT
| Immatics Press Release November 1, 2021 | 1 | 1 |
| --- | --- |
All posters presented at the poster hall will be made available as virtual ePosters throughout the SITC 36th Annual Meeting.
- END -
About ACTengine^®^IMA200 programs
Each of the product candidates of the IMA200 programs is based on Immatics’ proprietary ACTengine^®^ approach in which the patient’s own T cells are genetically engineered to express a novel, proprietary TCR directed against a defined cancer target. The modified T cells are then reinfused into the patient to attack the tumor, an approach also known as TCR-T. ACTengine^®^ programs IMA201, IMA202 and IMA203 are currently in clinical development for the treatment of solid tumor indications, both in the US and in Germany. IMA204 is currently in pre-clinical development. All ACTengine^®^ product candidates can be rapidly manufactured utilizing a proprietary manufacturing process designed to enhance T cell engraftment and persistence in vivo.
The ACTengine^®^T cell products are manufactured at the Evelyn H. Griffin Stem Cell Therapeutics Research Laboratory in collaboration with UTHealth. The ACTengine^®^ IMA200 Programs are co-funded by the Cancer Prevention and Research Institute of Texas (CPRIT).
About Immatics
Immatics combines the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors with the goal of enabling a robust and specific T cell response against these targets. This deep know-how is the foundation for our pipeline of Adoptive Cell Therapies and TCR Bispecifics as well as our partnerships with global leaders in the pharmaceutical industry. We are committed to delivering the power of T cells and to unlocking new avenues for patients in their fight against cancer.
For regular updates about Immatics, visit www.immatics.com. You can also follow us on Twitter and LinkedIn.
Formore information, please contact:
| For Media Inquiries | Investor Relations Contact |
|---|---|
| Jacob Verghese<br> or Stephanie May | Eric Goldstein or John Mullaly |
| Trophic<br> Communications | LifeSci Advisors |
| Phone:<br> +49 89 2388 7731 | Phone: +1 646 791 9729 or +1 617-429-3548 |
| Immatics Press Release November 1, 2021 | 1 | 2 |
| --- | --- |
| immatics@trophic.eu | egoldstein@lifesciadvisors.com or<br> jmullaly@lifesciadvisors.com |
|---|---|
| Immatics N.V. | |
| --- | --- |
| Anja Heuer | Jordan Silverstein |
| Director, Corporate Communications | Head of Strategy |
| Phone: +49 89 540415-606 | Phone: +1 281 810 7545 |
| media@immatics.com | InvestorRelations@immatics.com |
| Immatics Press Release November 1, 2021 | 1 | 3 |
| --- | --- |